Sweden
Dr. Jeppsson serves as the Chief Financial Officer at Vicore Pharma Holding AB (VICO), where he is responsible for capital markets strategy & execution, strategic & financial planning & financial reporting. Dr. Jeppsson brings extensive experience from the biopharmaceutical and financial industry. Dr. Jeppsson started out his career as a bench scientist working with both small molecules and biologics within preclinical R&D at AstraZeneca and later transitioned into the business side of biotech through positions as a healthcare equity research analyst at Danske Bank Markets and most recently as a CFO of Vicore Pharma. He holds an M.Sc. in Finance and a Ph.D. in Strategic Financial Management from the University of Gothenburg. He was a visiting scholar (2011) and a post-doctoral fellow (2015-2016) at Haas School of Business at the University of California, Berkeley. His research on corporate finance in biotechnology has appeared in leading academic and industry journals, including Journal of Corporate Finance, Journal of Applied Corporate Finance and Journal of Commercial Biotechnology. He also has a background in Chemical Engineering with a major in Biotechnology from Chalmers University of Technology.
Vicore Pharma is a rare disease company developing novel therapeutics for the treatment of fibrosis. • Raised external financing in excess of SEK1.6bn (through a rights issue and several private placements) • Up-listing from Nasdaq First North Growth Market to the Nasdaq Stockholm main list • Asset acquisition of INIM Pharma The company's shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.
Assistant professor in Finance (04/2015 – 05/2017); Research fellow (06/2017 –) Teaching experience in corporate valuation, venture capital, entrepreneurial finance, and corporate finance, all at advanced levels. Main research interests concern valuation, investment strategies, entrepreneurial finance, venture capital, IPOs, M&As, corporate finance with an application to the healthcare sector. Publications: • Jeppsson, H. (2018). Initial public offerings, subscription precommitments and venture capital participation. Journal of Corporate Finance 50, 650-668. #Award for the Best Paper at the 23rd Annual Global Finance Conference, Fresno, CA, USA, April 21-23, 2016 #Honorarium at the 2015 FMA Applied Finance Conference, May 15, 2015, New York, USA • Jeppsson, H. (2018). Biomarker of quality? Venture-backed biotech IPOs and insider participation. Journal of Applied Corporate Finance 30(1), 78-88. • Jeppsson, H. (2016). Leaving money on the table in venture-backed biotechnology IPOs. Journal of Commercial Biotechnology 22(4), 27-38. • Jeppsson, H. (2016). Biotech venture investments in public equities and performance. Journal of Commercial Biotechnology 22(4), 39-52.
• Sell side analyst covering Nordic healthcare equities. • Performance of investment research and responsible for financial modeling, valuation and analysis encompassing rNPV, market analysis, balance sheet and income projections. • Daily contact with global institutional clients externally and brokers internally. Meeting with key opinion leaders and key management, and arranging scientific meetings with investors. • Broad healthcare industry exposure including companies developing agents in the following areas: Oncology, cardiovascular, infectious diseases, inflammation and autoimmune diseases as well as other areas.
• Dept. of Molecular Pharmacology (Bioscience), AstraZeneca R&D: 2005 - 2006. Protein Chemistry. Characterisation of different forms of prothrombin using monoclonal antibodies and the Surface Plasmon Resonance (SPR) technology. • Synthetic chemistry/Multiple parallel synthesis, GABA-receptor project, Dept. of Lead Generation, AstraZeneca R&D: 2005 • Cheminformatics/Dept. of Medicinal Chemistry, AstraZeneca R&D: 2001 - 2003